Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy

被引：0
作者：
Ammar A. Javed
Michael J. Wright
Ayat Siddique
Alex B. Blair
Ding Ding
Richard A. Burkhart
Martin Makary
John L. Cameron
Amol Narang
Joseph Herman
Lei Zheng
Daniel Laheru
Matthew J. Weiss
Christopher Wolfgang
Jin He
机构：
[1] The Johns Hopkins University School of Medicine,Department of Surgery
[2] The Johns Hopkins University School of Medicine,The Pancreatic Cancer Precision Medicine Center of Excellence Program
[3] The Johns Hopkins University School of Medicine,Department of Oncology
[4] The Johns Hopkins University School of Medicine,Department of Radiation Oncology
来源：
Journal of Gastrointestinal Surgery | 2019年 / 23卷
关键词：
Borderline pancreatic cancer; Neoadjuvant therapy; Rate of resectability (Denominator); Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：112 / 121
页数：9
相关论文
共 136 条
  • [1] Siegel RL(2018)Cancer statistics, 2018 CA: a Cancer Journal for Clinicians. 68 7-30
  • [2] Miller KD(2013)Recent progress in pancreatic cancer CA: a Cancer Journal for Clinicians. 63 318-48
  • [3] Jemal A(2017)Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology Journal of the National Comprehensive Cancer Network: JNCCN. 15 1028-61
  • [4] Wolfgang CL(2014)Borderline resectable pancreatic cancer: definitions and management World Journal of Gastroenterology. 20 10740-51
  • [5] Herman JM(2013)Treatment of borderline resectable pancreatic cancer Current Treatment Options in Oncology. 14 293-310
  • [6] Laheru DA(2010)Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer HPB: the Official Journal of the International Hepato Pancreato Biliary Association 12 73-9
  • [7] Klein AP(2015)Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas Annals of Surgical Oncology. 22 1153-9
  • [8] Erdek MA(2009)Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement Annals of Surgical Oncology 16 1751-6
  • [9] Fishman EK(1995)Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Annals of Surgery. 221 59-66
  • [10] Tempero MA(2016)The role of neoadjuvant therapy in pancreatic cancer: a review Future Oncology. 12 669-85
12345678910